WuXi XDC Reports Impressive Growth in 2025, Solidifying Its Position in Bioconjugate CRDMO Market WuXi XDC’s 2025 financial performance reflects significant growth in revenue and market position, underscoring its role in bioconjugate CRDMO.

WuXi XDC Reports Impressive Growth in 2025, Solidifying Its Position in Bioconjugate CRDMO Market #China #Shanghai #WuXi_XDC #bioconjugate #CRDMO

WuXi XDC and Earendil Labs Join Forces to Innovate in Antibody-Drug Conjugate Technology WuXi XDC collaborates with Earendil Labs, leveraging AI to advance antibody-drug conjugate technology, focusing on treatment for significant medical needs.

WuXi XDC and Earendil Labs Join Forces to Innovate in Antibody-Drug Conjugate Technology #China #Shanghai #ADC_technology #WuXi_XDC #Earendil_Labs

Earendil Labs Partners with WuXi XDC to Advance ADC Technology with AI Innovations Earendil Labs collaborates with WuXi XDC to enhance next-generation antibody-drug conjugates using AI-driven technology, aiming for impactful medical advancements.

Earendil Labs Partners with WuXi XDC to Advance ADC Technology with AI Innovations #United_States #Wilmington #ADC_technology #WuXi_XDC #Earendil_Labs

WuXi XDC Achieves Remarkable Wins at 2025 World ADC Awards for CDMO and CRO WuXi XDC has secured top honors at the 2025 World ADC Awards, winning 'Best CDMO' and 'Best CRO.' These accolades highlight its leadership in the bioconjugate industry.

WuXi XDC Achieves Remarkable Wins at 2025 World ADC Awards for CDMO and CRO #China #Shanghai #WuXi_XDC #CRDMO #ADC_Awards

Highlights from the Successful 2025 BPD Singapore Conference on Biopharmaceutical Development The 2025 BPD Singapore Conference successfully concluded, promoting innovation in biopharmaceutical development and fostering global cooperation among key industry players.

Highlights from the Successful 2025 BPD Singapore Conference on Biopharmaceutical Development #biopharmaceuticals #Singapore #WuXi_XDC #BPD_Conference

WuXi XDC Reports Strong Revenue Growth and Continued Market Leadership in Bioconjugates for H1 2025 WuXi XDC showcases impressive financial performance in the first half of 2025, highlighting significant growth in revenue and market expansion in the bioconjugates sector.

WuXi XDC Reports Strong Revenue Growth and Continued Market Leadership in Bioconjugates for H1 2025 #China #Shanghai #WuXi_XDC #CRDMO #bioconjugates

WuXi XDC Celebrates Inclusion in MSCI China All Share Index Marking a New Milestone WuXi XDC, a leading Contract Research Organization, has been included in the MSCI China All Share Index, enhancing its exposure in global markets.

WuXi XDC Celebrates Inclusion in MSCI China All Share Index Marking a New Milestone #China #Shanghai #WuXi_XDC #CRDMO #MSCI_China

WuXi XDC Marks Milestone with GMP Release of DP3 Facility in Wuxi WuXi XDC has officially launched its DP3 facility in Wuxi, enhancing drug product manufacturing capacity and exemplifying commitment to quality.

WuXi XDC Marks Milestone with GMP Release of DP3 Facility in Wuxi #China #Wuxi #WuXi_XDC #DP3_Facility #GMP_Release

WuXi XDC Completes Mechanical Milestone in Singapore, Enhancing Global Bioconjugate Manufacturing Expansion WuXi XDC marks a significant milestone with the completion of its Singapore facility, set to boost global bioconjugate manufacturing capacities. Operations start in late 2025.

WuXi XDC Completes Mechanical Milestone in Singapore, Enhancing Global Bioconjugate Manufacturing Expansion #Manufacturing #Singapore #WuXi_XDC #bioconjugates

WuXi XDC Earns Six Prestigious Awards at 2025 Extel Rankings for Leadership and Governance WuXi XDC has achieved remarkable recognition by securing multiple prestigious awards at the 2025 Extel Rankings, showcasing its leadership and governance excellence in the bioconjugate sector.

WuXi XDC Earns Six Prestigious Awards at 2025 Extel Rankings for Leadership and Governance #China #Shanghai #WuXi_XDC #CRDMO #Extel_Awards

WuXi XDC Achieves Extraordinary Growth in 2024 with Record Financial Performance WuXi XDC celebrates significant milestones in 2024, reporting a remarkable 90.8% revenue increase driven by expanding customer base and innovative technologies, solidifying its leadership in the bioconjugate sector.

WuXi XDC Achieves Extraordinary Growth in 2024 with Record Financial Performance #China #Shanghai #ADC #WuXi_XDC #bioconjugate

WuXi XDC and AbTis Forge Strategic Alliance for Future ADC Advances WuXi XDC partners with AbTis to enhance next-generation ADCs through innovative technology integration, accelerating development in bioconjugates.

WuXi XDC and AbTis Forge Strategic Alliance for Future ADC Advances #China #Shanghai #ADC_technology #WuXi_XDC #AbTis

WuXi XDC and LigaChem Optimize ADC Development through Expanded Partnership WuXi XDC and LigaChem Biosciences have enhanced their collaboration with a new MOU to accelerate the development of next-gen ADC therapies, improving treatment options for cancer patients.

WuXi XDC and LigaChem Optimize ADC Development through Expanded Partnership #China #Shanghai #ADC_Development #WuXi_XDC #LigaChem